R
Roland L. Bassett
Researcher at University of Texas MD Anderson Cancer Center
Publications - 342
Citations - 14418
Roland L. Bassett is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 47, co-authored 308 publications receiving 11802 citations. Previous affiliations of Roland L. Bassett include AIDS Clinical Trials Group & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus
Roberto Lande,Dipyaman Ganguly,Dipyaman Ganguly,Valeria Facchinetti,Loredana Frasca,Curdin Conrad,Josh Gregorio,Josh Gregorio,Stephan Meller,Georgios Chamilos,Rosalie Sebasigari,Valeria Riccieri,Roland L. Bassett,Hideki Amuro,Shirou Fukuhara,Tomoki Ito,Yong-Jun Liu,Michel Gilliet +17 more
TL;DR: An important role is shown for neutrophils in lupus pathogenesis, whereby neutrophil activated by anti-self antibodies release NETs, which contain antimicrobial peptides complexed with self-DNA and can entrap bacteria, enabling them to be killed.
Journal ArticleDOI
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Journal ArticleDOI
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Ann C. Collier,Robert W. Coombs,David A. Schoenfeld,Roland L. Bassett,Joseph Timpone,Alice Baruch,Michelle Jones,Karen Facey,Caroline C. Whitacre,Vincent McAuliffe,Harvey M. Friedman,Thomas C. Merigan,Richard C. Reichman,Carol J. Hooper,Lawrence Corey +14 more
TL;DR: This drug combination reduced HIV-1 replication, increased CD4+ cell counts, and decreased levels of activation markers in serum more than did treatment with zidovudine and either saquinavir or zalcitabine.
Journal ArticleDOI
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macedo,Jacob Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei Shen Chen,Michael T. Tetzlaff,Russell J. Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna Pradyuman Patel,Patrick Hwu,Wen-Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Victor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo +43 more
TL;DR: It is demonstrated that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade.
Journal ArticleDOI
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
John A. Jakob,Roland L. Bassett,Chaan S. Ng,Jonathan L. Curry,Richard W. Joseph,Gladys Alvarado,Michelle Rohlfs,Jessie Richard,Jeffrey E. Gershenwald,Kevin B. Kim,Alexander J. Lazar,Patrick Hwu,Michael A. Davies +12 more
TL;DR: The prognostic significance and clinicopathologic correlations of v‐raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v‐ras) oncogen homolog (NRAS) mutations in patients with metastatic melanoma are tested.